A Too-Cheap Wholesaler, an Import Request, and a Supplement Claim
An independent Mississippi pharmacy's buyer forwards a cold email: a licensed wholesale distributor in another state offers generic apixaban 5 mg, 60-count bottles, at 45% below the pharmacy's primary wholesaler price, drop-shipped within 48 hours, with package pedigree available on request, minimum order 30 bottles. The pharmacy has never done business with this company and the buyer has not verified it. Separately, a patient brings in a package and asks the pharmacy to order the European version of a medicine approved in Germany but not in the United States, and to sell her a 90-day supply because it is cheaper. That same week a sales representative pitches a botanical product for the front-of-store shelf: the box front says clinically proven to lower A1C, while the small print says supports healthy blood sugar.
1. Should the pharmacy buy the discounted apixaban? What must be verified first?
Read the worked answer
No - not until the supply chain is verified, and probably not at all.
DSCSA / PDMA framework. A pharmacy may buy prescription drugs only from an authorized trading partner: a licensed wholesale distributor, a manufacturer or repackager registered with FDA. The pharmacy must obtain transaction information, transaction history, and a transaction statement, and must participate in electronic, interoperable exchange of transaction data.
Red flags here: an unsolicited cold offer; a 45% discount on a high-cost anticoagulant; an unverified new account; pedigree available only on request (the information is required, not optional); drop-ship arrangements that obscure the chain of custody. These are hallmarks of counterfeit, diverted, or stolen product.
Verify: the distributor's license in its home state and any nonresident wholesale license required to ship into Mississippi; FDA registration if it claims to be a manufacturer or repackager; references and history. When the price is implausible and the trading partner is unverified, the answer is no - the pharmacy, not the seller, owns the risk of introducing an adulterated or misbranded drug into commerce.
2. How do you handle the patient's request to order the European version?
Read the worked answer
The pharmacy cannot order it. A drug approved in Germany but not in the United States is an unapproved new drug; importing it and selling it violates 21 U.S.C. 355(a) and 331(d), and reimportation by anyone other than the manufacturer is also barred by 21 U.S.C. 353(c).
FDA's personal importation guidance is enforcement discretion for a patient bringing in a personal supply of a drug unavailable here - it is not an authorization, it does not extend to a pharmacy purchasing for resale, and it does not override state law or the prescription requirement.
Constructive path: explain the legal barrier, encourage the patient to discuss alternatives with her prescriber, and note that legitimate access routes exist - an FDA-approved alternative, a clinical trial, or expanded access (compassionate use) through the prescriber. Document the conversation. Do not reassure her that the pharmacy will somehow obtain it.
3. What do you do about the botanical product with the A1C claim?
Read the worked answer
It cannot be sold as labeled. A claim to lower A1C is a disease claim, which makes the product a drug under 21 U.S.C. 321(g)(1)(B) - an unapproved new drug and misbranded if marketed as a dietary supplement. DSHEA permits only structure/function statements (supports healthy blood sugar), and even those require the standard disclaimer and must be truthful and not misleading.
Clinically proven to lower A1C is also an advertising claim that must be substantiated, which exposes the seller to FTC action in addition to FDA action.
Practical steps: return or quarantine the product, notify the buyer and the rep in writing of the reason, and do not stock it in a modified-label form. A supplement aisle is not a safe harbor for drug claims.